Tasmanian biotech company, Marinova, has developed a proprietary method of extracting fucoidan from a particular variety of seaweed, an active material long-recognised in Asian cultures for its health benefits.  In an earlier Phase I/II human clinical trial, it was shown that this unique fucoidan compound is safely able to relieve the symptoms of osteoarthritis to levels similar to those achieved by non steroidal anti-inflammatory drugs. 

Commercialisation Australia funding will assist Marinova to validate fucoidan's efficacy claims in the treatment of osteoarthritis using a commercially viable dose and enter the large and growing global joint health market.